BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 33717103)

  • 1. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
    Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
    Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
    Oh E; Choi IK; Hong J; Yun CO
    Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 5. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
    Choi IK; Li Y; Oh E; Kim J; Yun CO
    PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
    Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
    Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
    Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
    Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
    Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
    Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
    Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
    Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
    Ye JF; Qi WX; Liu MY; Li Y
    Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
    Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
    Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.